On August 5, 2025, ADMA Biologics, Inc. secured a $300 million credit facility, including a $75 million term loan and a $225 million revolving credit, to refinance existing debts and support working capital. This agreement includes terms for interest and repayments and has implications for the company’s financial covenants.